Last reviewed · How we verify

total intravenous anesthetics

Università Vita-Salute San Raffaele · FDA-approved active Small molecule

Total intravenous anesthetics are a class of drugs that induce and maintain general anesthesia by depressing the central nervous system through enhancement of GABAergic inhibitory neurotransmission.

Total intravenous anesthetics are a class of drugs that induce and maintain general anesthesia by depressing the central nervous system through enhancement of GABAergic inhibitory neurotransmission. Used for Induction and maintenance of general anesthesia, Sedation in intensive care units.

At a glance

Generic nametotal intravenous anesthetics
SponsorUniversità Vita-Salute San Raffaele
Drug classGABA-A receptor agonist / General anesthetic
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

These agents work primarily by potentiating gamma-aminobutyric acid (GABA) signaling at GABA-A receptors in the brain, leading to hyperpolarization of neurons and reduced neuronal excitability. Common agents in this class include propofol, etomidate, and ketamine, each with distinct pharmacokinetic profiles and clinical properties. They are administered intravenously to rapidly induce unconsciousness and are often used for induction and maintenance of general anesthesia in surgical and critical care settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: